Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Alnylam
 More »

  • Ascletis Obtains Chinese Rights to Janssen HIV Treatment
    of liver cancers that is being developed with Alnylam Pharmaceuticals; and ASC-08 (danoprevir), a clinical-stage hepatitis C protease inhibitor being developed with Roche. ...
    4-30-2013
  • GEN | Biolinks
    Alimera Sciences Alkermes All India Bitoech Association Allergan Allinky Biopharma Allon Therapeutics Alnylam Pharmaceuticals Altathera Pharmaceuticals Althea Technologies, Inc. ...
  • Alnylam Losses Widened by Tekmira Settlement
    Alnylam Pharmaceuticals finished the fourth quarter and all of 2012 in the red, hurt by a ... Alnylam finished Q4 2012 with a net loss of $62.2 million or $1.20 per share on both a ...
    2-8-2013
  • Cholesterol Drug Deal Worth Up to $205M
    The Medicines Company will develop and commercialize for Alnylam Pharmaceuticals a series ... in the blood, in a collaboration that could net Alnylam as much as $205 million. ...
    2-4-2013
  • People in the News
    Patricia Allen Zafgen added Patricia Allen as CFO. Formerly, Allen served as vp of finance, treasurer, and principal financial officer of Alnylam Pharmaceuticals. Prior to that, ...
    2-1-2013
  • Top 20 Venture Capital Firms
    Current fund: $400 million ARCH Venture Fund VII, closed 2007 Biopharma portfolio companies: Achaogen, Acylin Therapeutics, Agios Pharmaceuticals, Allozyne, Alnylam Holdings, Array ...
    12-17-2012
  • Antisense Making Sense to Isis Partners
    In addition, Isis has ongoing collaborations with Genzyme, Alnylam, and GlaxoSmithKline. Isis' modus operandi is to discover and conduct early development of new drugs and then ...
    12-11-2012
  • Burying the Hatchet: Alnylam Settles Tekmira RNAi Suits
    Alnylam settled nearly two years of lawsuits over lipid nanoparticle (LNP) technology for ... Alnylam will pay $30 million to Tekmira to secure rights to manufacture its own LNP-based ...
    11-13-2012
  • The 10 Most Well-Connected People in Biotech
    ... engineering, 1972; M.D. in electrical engineering, 1970 John K. Clarke 4 58 years old Alnylam Pharmaceuticals, Co-Founder and Chairman, Board of Directors, 2002-present aTyr ...
    10-29-2012
  • Genzyme to Develop Alnylam's ATTR Drug in Asia
    Genzyme is paying Alnylam $22.5 million up front as part of an exclusive alliance to ... Alnylam aims to continue its own development and commercialization of ALN-TTR in the U.S., ...
    10-22-2012
  • Looking for jobs at DDT
    The Biotech companies that sent representatives included Archemix, Alkermes, Alnylam, Biogen Idec, Genzyme, Genentech, Millipore and Lonza Biologics. Quintiles Transnational, a ...
    8-14-2012
  • Biotech Valuations at trough levels
    ... Partners include BMS, GSK, Alnylam, TEVA , Ortho, and a blockbuster deal with Genzyme for $325 million in funding with a 50/50 profit sharing for a cardiovascular drug, an APO B ...
    8-13-2012
  • Clinical Application of miRNAs a Ways Off
    ... Regulus Therapeutics, established by Alnylam and Isis in September 2007, combines the companies' expertise in oligonucleotide chemistry to develop miRNA-targeted drugs. Regulus' ...
    8-1-2012
  • People in the News
    Taylor previously worked at MedImmune as senior director of marketing, RSV franchise and senior director of marketing, global influenza franchise. Alnylam Pharmaceuticals appointed ...
    8-1-2012
  • Flu Vaccine Manufacturing Gets Shot in Arm
    Alnylam Pharmaceuticals earned a development milestone payment from GlaxoSmithKline (GSK) ... The VaxiRNA platform stems from work Alnylam has performed as part of its Alnylam ...
    7-30-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll